Anvisa releases simplified prescription of medicinal cannabis and opens the way for export

Agência Nacional of Vigilância Sanitária published this Wednesday a resolution that transforms access to medical cannabis products into Brasil. The measure simplifies the prescription process and authorizes for the first time the export of plants grown in the country. The text was published on Diário Oficial of União and marks regulatory progress since the release of cultivation for medicinal purposes in February.
White Receita replaces more rigorous models
Produtos with THC content equal to or less than 0.2% now use Receita of Controle Especial, white document with two copies. One copy remains retained at the pharmacy and the other remains with the patient. Esse model has been used for years for antidepressants and some anxiolytics, reducing bureaucratic barriers for those who need the medication.

The change eliminates the need for yellow or blue recipes, which have a shorter shelf life and more rigorous control. The black stripe should gradually come off the packaging, although the standard allows purchases with the new recipe even on products with old labeling. Médicos qualified continue to be the only ones authorized to prescribe, with mandatory clinical monitoring throughout the treatment.
Exportação opens global market opportunity
Empresas Brazilian companies can now cultivate cannabis sativa for international sale, as long as the varieties contain THC of up to 0.3%. Produtores need to prove external demand with contracts or formal documents before starting operations. The cultivation of plants with THC above 0.3% remains restricted exclusively to scientific research.
Operações export products undergo strict inspection at ports and airports, with complete traceability of the material. The measure positions Brasil as a potential supplier in a segment that is growing in several countries, aligning with international conventions on controlled substances. Anvisa fits low THC material into special control rules, ensuring security in international transactions.
Principais regulation changes
- Produtos with THC up to 0.2% use special control white recipe instead of yellow or blue recipes
- Cultivo for export requires a maximum THC of 0.3% and proof of international demand
- Prescrição by veterinarians released for animals with regularized and registered products
- Fiscalização maintains control over all stages of production, dispensing and sales
- Tarja black gradually gives way to less restrictive labeling on packaging
Extensão for veterinary medicine
The resolution authorizes veterinarians to prescribe medicines and cannabis derivatives for animals. Products must have health authorization and registration with Ministério of Agricultura and Pecuária. The recipe follows a model similar to that used in human health, with one copy retained at the authorized establishment and the other delivered to the animal’s owner.
Pacientes and owners receive clear information about risks and benefits before treatment. The Termo of Consentimento Livre and Esclarecido remains mandatory, integrating the veterinary sector into the surveillance system already consolidated in human health.
Impacto on offer and access
Simplifying prescriptions can reduce costs and bureaucracy for patients who faced access difficulties with old prescriptions. Farmácias and distributors need to adapt to the new dispensing and traceability requirements. Anvisa reinforces that products without health registration remain prohibited, maintaining vigilance over the quality and safety of everything that reaches the market.
Profissionais healthcare professionals receive guidance for responsible prescribing, with a permanent focus on safety and quality. The standard updates the regulatory framework that has existed since 2019, giving predictability to the sector and expanding therapeutic options for cases where other treatments do not work properly.






